Fertility and Sterility
Volume 93, Issue 7 , Pages 2418-2420 , 1 May 2010

Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study

Presented at the Annual ESHRE Meeting, Amsterdam, June 28–July 1, 2009.

  • Daniel Bodri, M.D., M.S.

      Affiliations

    • Clínica EUGIN, Barcelona, Spain
    • Universitat Autònoma de Barcelona, Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva, Barcelona, Spain
    • Corresponding Author InformationReprint requests: Daniel Bodri, M.D. M.S., Clínica EUGIN, calle Entença 293-295, 08029 Barcelona, Spain (FAX: +34-93-227-56-05).
    • ,
  • Juan José Guillén, M.D.

      Affiliations

    • Clínica EUGIN, Barcelona, Spain
    • ,
  • Marta Trullenque, M.D.

      Affiliations

    • Clínica EUGIN, Barcelona, Spain
    • ,
  • Katja Schwenn, M.D.

      Affiliations

    • Clínica EUGIN, Barcelona, Spain
    • ,
  • Carolina Esteve, M.D.

      Affiliations

    • Clínica EUGIN, Barcelona, Spain
    • ,
  • Oriol Coll, M.D., Ph.D.

      Affiliations

    • Clínica EUGIN, Barcelona, Spain

Received 19 May 2009 ,Revised 4 July 2009 ,Accepted 11 August 2009.

References 

  1. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21:1260–1265
  2. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91
  3. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril. 2007;88:237–239
  4. Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365–371
  5. Hernandez ER, Gomez-Palomares JL, Ricciarelli E. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril. 2009;91(Suppl):1358–1361
  6. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86:1682–1687
  7. Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009;25:60–66
  8. Bodri D, Guillen JJ, Polo A, Trullenque M, Esteve C, Coll O. Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. Reprod Biomed Online. 2008;17:237–243
  9. van der Meer S, Gerris J, Joostens M, Tas B. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. Hum Reprod. 1993;8:1628–1631
  10. Chun E. Severe OHSS can be prevented in GnRH antagonist protocol using GnRH agonist to trigger ovulation. [abstract P-149] Fertil Steril. 2005;84(Suppl 1):S301
  11. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod. 2007;22:1348–1352
  12. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–261
  13. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9:275–289
  14. Álvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92:2931–2937
  15. Fabregues F, Balasch J, Manau D, Jimenez W, Arroyo V, Creus M, et al. Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Hum Reprod. 1998;13:2406–2410
  16. Fabregues F, Balasch J, Gines P, Manau D, Jimenez W, Arroyo V, et al. Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. Am J Gastroenterol. 1999;94:994–999
  17. Garcia-Velasco JA, Quea G, Piro M, Mayoral M, Ruiz M, Toribio M, et al. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril. 2009;92:222–225
  18. Giles J, Requena A, Garcia-Velasco JA, Pacheco A, Pellicer J, Pellicer A. GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. Fertil Steril. 2009;91(Suppl):1366–1369
  19. Kol S, Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?. J Assist Reprod Genet. 2008;25:63–66

 D.B. has nothing to disclose. J.J.G. has nothing to disclose. M.T. has nothing to disclose. K.S. has nothing to disclose. C.E. has nothing to disclose. O.C. has nothing to disclose.

PII: S0015-0282(09)03514-6

doi: 10.1016/j.fertnstert.2009.08.036

Fertility and Sterility
Volume 93, Issue 7 , Pages 2418-2420 , 1 May 2010

Article Tools